Matches in SemOpenAlex for { <https://semopenalex.org/work/W4380291236> ?p ?o ?g. }
Showing items 1 to 91 of
91
with 100 items per page.
- W4380291236 endingPage "311" @default.
- W4380291236 startingPage "303" @default.
- W4380291236 abstract "This multicenter, randomized, double-blind, placebo-controlled phase 2 trial compared the efficacy, and safety of adding pyrotinib to trastuzumab, docetaxel, and carboplatin versus placebo, trastuzumab, docetaxel, and carboplatin in Chinese patients with human epidermal receptor 2 (HER2)-positive early or locally advanced breast cancer (<ext-link ext-link-type=uri xlink:href=http://ClinicalTrials.gov xmlns:xlink=http://www.w3.org/1999/xlink>ClinicalTrials.gov</ext-link> identifier: NCT03756064).Sixty-nine women with HER2-positive early (T1-3, N0-1, M0) or locally advanced breast cancer (T2-3, N2 or N3, M0; T4, any N, M0) were recruited from October 1, 2019, to June 1, 2021. Before surgery, patients received 6 cycles of orally pyrotinib (400 mg once per day), trastuzumab (8-mg/kg loading dose and 6-mg/kg maintenance doses), docetaxel (75 mg/m2), and carboplatin (AUC = 6 mg/mL·min) or orally placebo, trastuzumab, and docetaxel, and carboplatin every 3 weeks. The primary end point was independent review committee-assessed total pathologic complete response rate. The 2-sided Cochran-Mantel-Haenszel test, stratified by age, hormone receptor status, tumor stage, nodal status, cTNM stage, and Ki-67 level was used to compare rates between treatment groups.In total, 69 female patients were randomized (pyrotinib, 36; and placebo, 33; median age, 53 [31-69] years). In the intention-to-treat population, total pathologic complete response rates were 65.5% (19/29) in the pyrotinib group and 33.3% (10/30) in the placebo group (difference, 32.2%, p = 0.013). Diarrhea was been reported in 86.1% of patients (31/36) in the pyrotinib group as the most common adverse events (AEs) and 15.2% of patients (5/33) in the placebo group. But no grade 4 or 5 AEs were reported.Treatment with pyrotinib, trastuzumab, docetaxel, and carboplatin resulted in a statistically significant improvement in the total pathologic complete response rate versus placebo, trastuzumab, docetaxel, and carboplatin for the neoadjuvant treatment of HER2-positive early or locally advanced breast cancer in Chinese patients. Safety data were in line with the known pyrotinib safety profile and generally comparable between treatment groups." @default.
- W4380291236 created "2023-06-13" @default.
- W4380291236 creator A5010559849 @default.
- W4380291236 creator A5016406818 @default.
- W4380291236 creator A5033542000 @default.
- W4380291236 creator A5034882484 @default.
- W4380291236 creator A5041509753 @default.
- W4380291236 creator A5044670575 @default.
- W4380291236 creator A5048485599 @default.
- W4380291236 creator A5055843989 @default.
- W4380291236 creator A5060148518 @default.
- W4380291236 creator A5063382829 @default.
- W4380291236 creator A5069136185 @default.
- W4380291236 creator A5092141812 @default.
- W4380291236 date "2023-01-01" @default.
- W4380291236 modified "2023-10-01" @default.
- W4380291236 title "Neoadjuvant Pyrotinib plus Trastuzumab, Docetaxel, and Carboplatin in Early or Locally Advanced Human Epidermal Receptor 2-Positive Breast Cancer in China: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial" @default.
- W4380291236 doi "https://doi.org/10.1159/000531492" @default.
- W4380291236 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37302393" @default.
- W4380291236 hasPublicationYear "2023" @default.
- W4380291236 type Work @default.
- W4380291236 citedByCount "1" @default.
- W4380291236 countsByYear W43802912362023 @default.
- W4380291236 crossrefType "journal-article" @default.
- W4380291236 hasAuthorship W4380291236A5010559849 @default.
- W4380291236 hasAuthorship W4380291236A5016406818 @default.
- W4380291236 hasAuthorship W4380291236A5033542000 @default.
- W4380291236 hasAuthorship W4380291236A5034882484 @default.
- W4380291236 hasAuthorship W4380291236A5041509753 @default.
- W4380291236 hasAuthorship W4380291236A5044670575 @default.
- W4380291236 hasAuthorship W4380291236A5048485599 @default.
- W4380291236 hasAuthorship W4380291236A5055843989 @default.
- W4380291236 hasAuthorship W4380291236A5060148518 @default.
- W4380291236 hasAuthorship W4380291236A5063382829 @default.
- W4380291236 hasAuthorship W4380291236A5069136185 @default.
- W4380291236 hasAuthorship W4380291236A5092141812 @default.
- W4380291236 hasConcept C121608353 @default.
- W4380291236 hasConcept C126322002 @default.
- W4380291236 hasConcept C142724271 @default.
- W4380291236 hasConcept C143998085 @default.
- W4380291236 hasConcept C168563851 @default.
- W4380291236 hasConcept C203092338 @default.
- W4380291236 hasConcept C204787440 @default.
- W4380291236 hasConcept C27081682 @default.
- W4380291236 hasConcept C2776694085 @default.
- W4380291236 hasConcept C2778239845 @default.
- W4380291236 hasConcept C2779786085 @default.
- W4380291236 hasConcept C2781190966 @default.
- W4380291236 hasConcept C2781451048 @default.
- W4380291236 hasConcept C2908647359 @default.
- W4380291236 hasConcept C530470458 @default.
- W4380291236 hasConcept C71924100 @default.
- W4380291236 hasConcept C99454951 @default.
- W4380291236 hasConceptScore W4380291236C121608353 @default.
- W4380291236 hasConceptScore W4380291236C126322002 @default.
- W4380291236 hasConceptScore W4380291236C142724271 @default.
- W4380291236 hasConceptScore W4380291236C143998085 @default.
- W4380291236 hasConceptScore W4380291236C168563851 @default.
- W4380291236 hasConceptScore W4380291236C203092338 @default.
- W4380291236 hasConceptScore W4380291236C204787440 @default.
- W4380291236 hasConceptScore W4380291236C27081682 @default.
- W4380291236 hasConceptScore W4380291236C2776694085 @default.
- W4380291236 hasConceptScore W4380291236C2778239845 @default.
- W4380291236 hasConceptScore W4380291236C2779786085 @default.
- W4380291236 hasConceptScore W4380291236C2781190966 @default.
- W4380291236 hasConceptScore W4380291236C2781451048 @default.
- W4380291236 hasConceptScore W4380291236C2908647359 @default.
- W4380291236 hasConceptScore W4380291236C530470458 @default.
- W4380291236 hasConceptScore W4380291236C71924100 @default.
- W4380291236 hasConceptScore W4380291236C99454951 @default.
- W4380291236 hasIssue "7-8" @default.
- W4380291236 hasLocation W43802912361 @default.
- W4380291236 hasLocation W43802912362 @default.
- W4380291236 hasOpenAccess W4380291236 @default.
- W4380291236 hasPrimaryLocation W43802912361 @default.
- W4380291236 hasRelatedWork W2004818507 @default.
- W4380291236 hasRelatedWork W2052405826 @default.
- W4380291236 hasRelatedWork W2057964951 @default.
- W4380291236 hasRelatedWork W2091007248 @default.
- W4380291236 hasRelatedWork W2781041469 @default.
- W4380291236 hasRelatedWork W4232759728 @default.
- W4380291236 hasRelatedWork W4232824905 @default.
- W4380291236 hasRelatedWork W4243445535 @default.
- W4380291236 hasRelatedWork W4255825072 @default.
- W4380291236 hasRelatedWork W4298186602 @default.
- W4380291236 hasVolume "46" @default.
- W4380291236 isParatext "false" @default.
- W4380291236 isRetracted "false" @default.
- W4380291236 workType "article" @default.